An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer

Trial Profile

An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms iNSITE-1
  • Sponsors BIND Therapeutics
  • Most Recent Events

    • 14 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 06 Apr 2016 Results published in a Bind Therapeutics media release.
    • 15 Mar 2016 According to Bind Therapeutics media release, company is expecting top-line results of full 40 patients in April 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top